Table 3.
Comparison of HAD-A, HAD-D, SF-36, ASEX, and laboratory results of baseline (base) and final sixth month (final) visits in inflammatory bowel disease outpatient population who diagnosed a psychiatric disorder with SCID
| Group A
|
Group B
|
||||
|---|---|---|---|---|---|
| (n=47)
|
(n=20)
|
||||
| Object | Mean ± SD | P-value | Object | Mean ± SD | P-value |
| HAD-A | <0.001 | HAD-A | 0.811 | ||
| Base | 12.38±4.38 | Base | 11.40±4.60 | ||
| Final | 5.97±4.45 | Final | 11.05±4.40 | ||
| HAD-D | <0.001 | HAD-D | 0.203 | ||
| Base | 10.62±3.61 | Base | 11.55±2.85 | ||
| Final | 3.53±4.01 | Final | 10.15±3.51 | ||
| Sf-1 | <0.001 | Sf-1 | 0.098 | ||
| Base | 51.44±26.49 | Base | 68.50±31.37 | ||
| Final | 73.00±22.69 | Final | 54.00±27.22 | ||
| Sf-2 | <0.001 | Sf-2 | 0.285 | ||
| Base | 25.00±34.12 | Base | 46.25±43.13 | ||
| Final | 60.55±34.74 | Final | 32.50±30.45 | ||
| Sf-3 | <0.001 | Sf-3 | 0.050 | ||
| Base | 42.71±24.24 | Base | 58.70±22.49 | ||
| Final | 58.11±21.26 | Final | 44.45±22.75 | ||
| Sf-4 | <0.001 | Sf-4 | 0.052 | ||
| Base | 28.17±16.64 | Base | 40.65±18.71 | ||
| Final | 48.88±22.30 | Final | 27.00±24.23 | ||
| Sf-5 | <0.001 | Sf-5 | 0.196 | ||
| Base | 33.55±19.29 | Base | 43.75±22.87 | ||
| Final | 57.66±23.75 | Final | 34.50±21.57 | ||
| Sf-6 | <0.001 | Sf-6 | 0.478 | ||
| Base | 42.50±23.89 | Base | 47.50±21.68 | ||
| Final | 61.38±20.78 | Final | 41.25±24.70 | ||
| Sf-7 | <0.001 | Sf-7 | 0.135 | ||
| Base | 29.62±38.41 | Base | 43.33±37.61 | ||
| Final | 65.17±38.24 | Final | 26.66±29.81 | ||
| Sf-8 | <0.001 | Sf-8 | 0.042 | ||
| Base | 40.44±16.60 | Base | 46.40±16.74 | ||
| Final | 62.04±17.96 | Final | 32.40±19.33 | ||
| ASEX 1 | <0.001 | ASEX 1 | 0.766 | ||
| Base | 3.95±1.31 | Base | 3.08±1.38 | ||
| Final | 2.48±1.27 | Final | 2.92±1.32 | ||
| ASEX 2 | <0.001 | ASEX 2 | 0.625 | ||
| Base | 3.69±1.47 | Base | 2.91±1.22 | ||
| Final | 2.38±1.47 | Final | 3.18±1.25 | ||
| ASEX 3 | <0.001 | ASEX 3 | 1.000 | ||
| Base | 3.51±1.39 | Base | 2.77±1.16 | ||
| Final | 2.33±1.28 | Final | 2.76±1.23 | ||
| ASEX 4 | <0.001 | ASEX 4 | 0.820 | ||
| Base | 3.55±1.51 | Base | 3.00±0.85 | ||
| Final | 2.26±1.42 | Final | 2.91±1.31 | ||
| ASEX 5 | <0.001 | ASEX 5 | 0.202 | ||
| Base | 3.43±1.40 | Base | 2.33±1.15 | ||
| Final | 2.05±1.31 | Final | 3.08±1.31 | ||
| ASEX T | <0.001 | ASEX T | 0.210 | ||
| Base | 17.89±6.01 | Base | 14.00±4.24 | ||
| Final | 11.43±5.62 | Final | 16.54±4.78 | ||
| CRP | 0.324 | CRP | 0.949 | ||
| Base | 6.58±13.89 | Base | 4.30±3.79 | ||
| Final | 4.61±4.03 | Final | 4.35±3.47 | ||
| WBC | 0.581 | WBC | 0.576 | ||
| Base | 6.50±1.94 | Base | 7,161±2,114 | ||
| Final | 6.39±1.93 | Final | 7,483±2,136 | ||
| Hb | 0.023 | Hb | 0.102 | ||
| Base | 12.40±1.60 | Base | 13.49±1.59 | ||
| Final | 12.86±1.15 | Final | 13.72±1.58 | ||
| Htc | 0.429 | Htc | 0.477 | ||
| Base | 37.79±4.30 | Base | 40.65±4.25 | ||
| Final | 38.25±3.04 | Final | 40.96±4.32 | ||
| Plt | 0.112 | Plt | 0.041 | ||
| Base | 290,097±92,872 | Base | 269,000±83,882 | ||
| Final | 279,707±91,409 | Final | 293,444±113,376 | ||
| MCV | 0.281 | MCV | 0.041 | ||
| Base | 85.57±7.37 | Base | 87.72±4.40 | ||
| Final | 84.69±7.69 | Final | 86.35±3.21 | ||
| MMS | 0.054 | MMS | 0.464 | ||
| Base | 2.71±3.05 | Base | 2.78±3.42 | ||
| Final | 0.94±1.91 | Final | 1.77±1.98 | ||
| CDAI | 0.011 | CDAI | 0.710 | ||
| Base | 197.41±130.60 | Base | 58.50±74.94 | ||
| Final | 101.08±65.88 | Final | 83.50±62.68 | ||
Notes: ASEX 1, drive; ASEX 2, arousal; ASEX 3, penile erection/vaginal lubrication; ASEX 4, ability to reach orgasm; ASEX 5, satisfaction from orgasm; base, baseline visit; final, final visit; Sf1: SF-36: physical functioning; Sf2, SF-36: role physical; Sf3, SF-36: bodily pain; Sf4, SF-36: general health; Sf5, SF-36: vitality; Sf6, SF-36: social functioning; Sf7, SF-36: role emotional; Sf8, SF-36: mental health. Group A: patients maintained psychiatric drug therapy during 6 months; Group B: patients could not maintain psychiatric drug therapy of 6 months. All boldface values are statistically significant values.
Abbreviations: ASEX T, ASEX total; CD, Crohn’s disease; CDAI, Crohn’s disease activity index; CRP, C reactive protein; DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, fourth edition; HAD-A, Hospital Anxiety and Depression Scale Anxiety score; HAD-D, Hospital Anxiety and Depression Scale Depression score; Hb, hemoglobin; Htc, hematocrit; IBD, inflammatory bowel disease; MCV, mean corpuscular volume; MMS, modified Mayo score; Plt, platelet; SCID, Structured Clinical Interview for DSM-IV Axis 1 Disorders; SF-36, Short Form-36; UC, ulcerative colitis; WBC, white blood cell.